• 한국버섯학회지
• /
• 제8권3호
• /
• pp.91-95
• /
• 2010

본 연구에서는 혈당강하 소재로서 가능성이 확인된 GFPC와 잎새버섯 및 흰목이 추출 혼합물의 안전성을 평가하기 위하여 수행되었었다. 마우스에 대한 급성경구독성을 평가하기 위해 체중 kg 당 최고 5g의 각 시험물질을 마우스 위에 직접 투여하여 48시간 동안 관찰 한 결과 모든 실험군에서 사망예가 관찰되지 않아 LD50 은 5g/kg B.W. 이상으로 계산되었으며, 임상 증상이나 체중에서도 유의할만한 소견이 관찰되지 않았다. 따라서 본 실험의 GFPC와 잎새버섯 및 흰목이 추출 혼합물은 마우스에 있어서 단기 급성 경구독성이나 부작용을 유발하지 않는 안전한 식품소재로 평가되었다. 결론적으로 GFPC와 잎새버섯 및 흰목이 추출 혼합물은 급성 독성이나 부작용을 유발하지 않아 임상사용의 가능성을 제시하여 주었다.

• 한국약용작물학회지
• /
• 제22권4호
• /
• pp.276-288
• /
• 2014

The six polysaccharide fractions were prepared by chromatographic procedure from the hot water extracts of the aboveground parts of Astragalus membranaceus. These six polysaccharides from aboveground parts of Astragalus membranaceus Bunge were tested for gut-mucosal immune activity and acute toxicity. In a view of molecular weight, the six fractions were estimated to be 75000, 88000, 129000 and 345000 Da, respectively. Component sugar analysis indicated that these fractions were mainly consisted of galactose (46.3 ~ 11.8%) and arabinose (35.4 ~ 9.9%) in addition to glucose, rhamnose, fucose, arabinose, xylose, mannose, glucuronic acid and galacturonic acid. Among the six major purified polysaccharides, AMA-1-b-PS2 showed highest bone merrow cell proliferation and lymphocyte of Peyer's patch stimulating activity. It may be concluded that intestinal immune system modulating activity of aboveground parts from Astragalus membranaceus Bunge is caused by polysaccharides having a polygalacturonan moiety with neutral sugars such as arabinose and galactose. In single oral dose toxicity study, no differences were observed between control and treated groups in clinical signs. The results indicated that lethal dose 50 ($LD_{50}$) of water extracts from Astragalus membranaceus-aboveground parts was found to be higher than 5000 mg/kg/day in this experiment. From the above results, we may suggest that Astragalus membranaceus-aboveground parts might have useful as a safe material for functional food and pharmaceutics.

• 농약과학회지
• /
• 제7권4호
• /
• pp.271-279
• /
• 2003

IAP-3006 원제(지베렐린산)의 SD계 랫드에 대한 아급성 경구 독성시험을 위하여 랫드에 1,000, 10,000과 15,000 ppm의 시험물질을 분말사료에 혼입하는 방법으로 주 5일, 90일간 경구 투여하여 그 독성과 안전성을 조사하였다. 전 시험기간 동안 모든 시험군의 동물에서 어떠한 임상 증상과 사망동물은 관찰되지 않았으며, 또한 체중변화, 사료 음수섭취량, 안과학적 검사, 뇨 검사 및 부검소견에서도 유의성 있는 변화는 보이지 않았다. 비록 혈액학적 검사, 혈액생화학적 검사 및 장기중량에서 유의성 있는 변화를 보였으나 모두 정상 범위에서의 변화이고 용량 의존적으로 나타나지 않았으며, 병리학적 소견에 있어서도 대조군과 비교하여 특이하게 다른 병변은 관찰되지 않았다. 이상의 결과로부터 IAP-3006 원제는 최고 투여용량인 15,000 ppm 에서도 유의할 만한 독성이 유발되지 않았으므로 안전한 것으로 판단되었으며, 무해용량은 15,000 ppm 이상으로 추정되었다.

• 한국식품영양과학회지
• /
• 제36권5호
• /
• pp.527-533
• /
• 2007

건강효능이 우수한 고품질 유색미 과피의 안전성 규명을 목적으로 ICR계 마우스 암수 각각 10마리를 이용하여 적진주벼, 흑진주벼 및 흑향벼 과피를 80% EtOH로 추출한 농축물을 1회 경구투여 후 14일 동안 실시한 급성독성 평가 결과는 다음과 같다. 시험물질을 1회 경구투여한 경우, 총 14일의 실험기간 동안 모든 시료투여군의 암수 동물에서 정상적인 체중증가가 관찰되었으며, 체중증가는 유의적인 차이를 나타나지 않았으며, 시료투여군의 경우 용량의존적인 체중변화도 관찰되지 않았다. 시험물질 투여 14일 후 부검결과, 암수 모든 실험군의 간장, 신장(좌, 우), 비장, 심장, 폐 및 뇌에서 시험물질 투여에 따른 어떤 육안적 이상 소견도 발견되지 않았다. 치사시킨 동물의 혈액 생화학적 검사 결과, 모든 시료 투여군의 ALT와 AST 활성도가 정상 수치를 나타냈으며, 본 실험의 최고 용량인 10.0 g/kg투여에도 정상치를 나타내는 것으로 보아, 유색미 과피 추출물을 10.0 g/kg 이하 섭취할 경우에는 어떠한 간독성도 나타내지 않음을 확인할 수 있었다. 이상의 실험결과를 통해 고품질 유색미인 적진주벼, 흑진주벼 및 혹향벼 과피 추출물의 단회 경구투여에 의한 독성시험 시, 시험물질 투여에 의한 표적 장기가 관찰되지 않았으며, 어떠한 독성학적인 변화도 관찰되지 않는 것으로 보아, 무해 용량은 암수 모두 10.0 g/kg을 상회할 것으로 추정할 수 있었다.

• 동의생리병리학회지
• /
• 제24권1호
• /
• pp.134-142
• /
• 2010

Although BinSo-San(BSS), a mixed herbal formula consisted of 11 types of medicinal herbs and have been used as anti-inflammatory agent, In the present study, the acute toxicity (single oral dose toxicity) of lyophilized BSS aqueous extracts was monitored in male and female mice after oral administration according to Korea Food and Drug Administration (KFDA) Guidelines (2005-60, 2005). In order to observe the 50% lethal dose ($LD_{50}$), approximate lethal dosage (ALD), maximum tolerance dosage (MTD) and target organs, test articles were once orally administered to female and male ICR mice at dose levels of 2000, 1000, 500, 250 and 0 (control) mg/kg (body wt.) according to the recommendation of KFDA Guidelines (2005-60, 2005). The mortality and changes on body weight, clinical signs and gross observation were monitored during 14 days after dosing according to KFDA Guidelines (2005-60, 2005) with organ weight and histopathology of 12 types of principle organs. We could not find any mortality, clinical signs and changes in the body weights except for dose-independent increases of body weight and gains restricted in 1000 mg/kg of BSS extracts-dosing female group. Hypertrophic changes of lymphoid organs.thymus, spleen and popliteal lymph nodes were detectedat postmortem observation with BSS extracts dose-dependent increases of lymphoid organ weights, and hyperplasia of lymphoid cells in these all three lymphoid organs at histopathological observations. These changes are considered as results of pharmacological effects of BSS extracts or their components, immunomodulating effects, not toxicological signs. In addition, some sporadic accidental findings such as congestion spots, cyst formation in kidney, atrophy of thymus and spleen with depletion of lymphoid cells, and edematous changes of uterus with desquamation of uterus mucosa as estrus cycles were detected throughout the whole experimental groups including both male and female vehicle controls. The significant (p<0.01) increases of absolute weights of kidney and pancreas detected in BSS extracts 1000 mg/kg-treated female group are considered as secondary changes from increases of body weights. The results obtained in this study suggest that the BSS extract is non-toxic in mice and is therefore likely to be safe for clinical use. The LD50 and ALD of BSS aqueous extracts in both female and male mice were considered as over 2000 mg/kg because no mortalities were detected upto 2000 mg/kg that was the highest dose recommended by KFDA and OECD. In addition, the MTD of BSS extracts was also considered as over 2000 mg/kg because no BSS extracts-treatment related toxicological signs were detected at histopathological observation except for BSS or their component-related pharmacological effects, the immunomodulating effects detected in the present study.

• Toxicological Research
• /
• 제23권3호
• /
• pp.253-261
• /
• 2007

In this study, we investigated the in vitro anti-obesity, anti-cancer activity and single oral dose toxicity of Inonotus xeranticus extracted by methanol (INXM) or ethyl acetate (INXE). In order to investigate anti-obestity effect of Inonotus xeranticus extracts, the 3T3-L1 cells were treated with these extracts at various concentrations(1, 10, 100 and $300{\mu}g/ml$). It was observed that 3T3-L1 cells treated with $100{\mu}g/ml$ of Inonotus obliquus ethyl acetate extract (INOE), INXM and INXE, in the absence of differentiation cocktail (0.5mM isobutylmethylxanthine (IBMX) $1{\mu}M$ dexamethasone, $1{\mu}M$ insulin), differentiated at a rate of 78.5, 80.9, and 76.4% respectively. Differentiation rates of 86.6% and 83.4% were observed in 3T3-L1 cells which were treated with differentiation cocktail at $100{\mu}g/ml$ of INXM and INXE, respectively. The anti-cancer effect of Inonotus xeranticus extracts was investigated using a method of sulforhodamine B in sarcoma 180 cell line. The cells were treated with these extracts (1, 10, 100 and $300{\mu}g/ml$) for 48 hours. The growth of cells which were treated with $300{\mu}g/ml$ of INXM was inhibited by 80.1%. The growth of sarcoma 180 cells which were treated with 100 and $300{\mu}g/ml$ of INXE was inhibited by 74.7% and 64.5%, respectively. In single oral dose toxicity study, no differences were observed between control and treated groups in clinical signs, body weight gains, and feed and water consumptions. The results indicated that Inonotus xeranticus extracts did not show any toxic effects at 2,000mg/kg in mice, and the $LD_{50}$ of these extracts was found to be higher than 2,000 mg/kg in this experiment. From the above results, Inonotus xeranticus methanol and ethyl acetate extracts might have useful clinical applications in the management of cancer and obesity and may also be useful as a medicinal food.

• 대한두경부종양학회지
• /
• 제27권1호
• /
• pp.47-53
• /
• 2011

Purpose : Concurrent chemoradiotherapy(CCRT) with 3 weekly cisplatin is the standard treatment of locally advanced head and neck cancer(HNC). The aim is to evaluate the efficacy and toxicities of low-dose weekly cisplatin-based CCRT, which was devised to reduce the toxicity of CCRT. Method : We retrospectively analyzed HNC patients who received low-dose weekly cisplatin-based CCRT between 2008 and 2010. Cisplatin 35mg/$m^2$ was weekly given to all patients during radiotherapy. The efficacy was evaluated by the degree of clinical response, treatment failure and survival. The toxicity was evaluated by hematologic toxicities and oral mucositis. Results : A total of 27 patients were analyzed and median age was 59(range 31-81). The ratio of administered dose of radiotherapy and cisplatin to planned dose were 0.98 and 0.93, respectively. Complete remission and partial remission were 73% and 23%, respectively. Treatment failure was observed in 8(30%) patients. 1-year survival rate and 1-year disease free survival rate were 82% and 59%, respectively. Overall survival and progression-free survival did not reach median time. Grade 3/4 anemia, neutropenia, thrombocytopenia and oral mucositis were observed in 11%, 19%, 7% and 32% of patients, respectively. In terms of administered cycles, however, only 1-3% of grade 3/4 hematologic toxicities occurred among total 190 cycles. Severe oral mucositis were statistically associated with old age(p=0.003). Treatment failure had no statistical relation with age, pathology, primary site and stage. Conclusion : Low-dose weekly cisplatin-based CCRT seemed to deliver enough dose of cisplatin and to show low drop-out rate and good efficacy with low hematologic toxicities.

• 치위생과학회지
• /
• 제18권3호
• /
• pp.188-193
• /
• 2018

The aim of the current study was to demonstrate the potential therapeutic efficacy of resveratrol in oral cancer patients. Lysophosphatidic acid (LPA) intensifies cancer cell invasion and metastasis, whereas resveratrol, a natural polyphenolic compound, possesses antitumor activity, suppressing cell proliferation and progression in various cancer cell lines (ovarian, gastric, oral, pancreatic, colon, and prostate cancer cells). In addition, resveratrol has been identified as an inhibitor of LPA-induced proteolytic enzyme expression and ovarian cancer invasion. Furthermore, resveratrol was shown to inhibit oral cancer cell invasion by downregulating hypoxia-inducible factor $1{\alpha}$ and vascular endothelial growth factor expression. Recently, we demonstrated that LPA is important for the expression of transcription factors TWIST and SLUG during epithelial-mesenchymal transition (EMT) in oral squamous carcinoma cells. In this study, we treated serum-starved cultures of oral squamous carcinoma cell line YD-10B with resveratrol for 24 hours prior to stimulation with LPA. To identify an optimal resveratrol concentration that does not induce apoptosis in oral squamous carcinoma cells, we determined the toxicity of resveratrol in YD-10B cells by assessing their viability using the MTT assay. Another assay was performed using Matrigel-coated cell culture inserts to detect oral cancer cell invasion activity. Immunoblotting was applied for analyzing protein expression of SLUG, TWIST1, E-cadherin, and GAPDH. We demonstrated that resveratrol efficiently inhibited LPA-induced oral cancer cell EMT and invasion by downregulating SLUG and TWIST1 expression. Therefore, resveratrol may potentially reduce oral squamous carcinoma cell invasion and metastasis in oral cancer patients, improving their survival outcomes. In summary, we identified new targets for the development of therapies against oral cancer progression and characterized the therapeutic potential of resveratrol for the treatment of oral cancer patients.

• 대한예방한의학회지
• /
• 제17권2호
• /
• pp.157-168
• /
• 2013

The objective of this study was to characterize the adverse effects of Ahnjon-Yichun-Tang during early pregnancy. Following successful mating, female Sprague-Dawley rats were given Ahnjon-Yichun-Tang(AYT) extract by oral administration daily with dose of 150mg (n=10), 300mg(n=10), 450mg(n=10) for 20 days of pregnancy. The rats in Control group(n=10) were orally administrated with Saline. All pregnant rats of Ahnjon-Yichun-Tang-treated and Control groups were sacrificed on day 20 of pregnancy. The pregnancy outcome was determined and the internal and reproductive organs of pregnant rat were observed. The fetuses were examined for the presence of various developmental toxic endpoints and stained with alcian blue and alizarin red S, and observed skeletal malformations. The results obtained in this study represent that there is no significant changes between Control and Ahnjon-Yichun-Tang-treated groups in body weight, organ weight, blood chemistry values, hematological values and pregnancy indexes of pregnant rat. The skeletal malformation of fetus was not observed as well. These results suggest that oral administration of Ahnjon-Yichun-Tang does not produce either maternal or developmental toxicity.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권8호
• /
• pp.4107-4112
• /
• 2012

4-Nitroquinoline 1-oxide (4-NQO) a potent oral carcinogen, widely used for induction of oral carcinogenesis, has been found to induce lipid peroxidation in vivo and in vitro. Green tea contains a high content of polyphenols, which are potent antioxidants. Thus green tea polyphenols (GTP) might be expected play a protective role against 4-NQO induced lipid peroxidation and bone marrow toxicity. In the present study, a dose of 200 mg of GTP/kg b.wt/day was given orally for a week, simultaneously animals received 0.2 ml of 0.5% 4-NQO in propylene glycol (5 mg/ml) injected intramuscularly for three times/week. Oxidants and antioxidants such as malendialdehyde (MDA) and thiols, glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD) and catalase (CAT) were significantly decreased in 4-NQO induced animals except MDA, and these parameters were brought back to near normalcy on treatment with GTP. The results suggest that GTP treatment offers significant protection against 4-NQO induced lipid peroxidation and bone marrow toxicity and might be a promising potential candidate for prevention of mutations leading to cancer.